Spectrum Pharmaceuticals to Present at the BioMilano 2003 Italian Partnering Conference
IRVINE, Calif., Nov. 21, 2003 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. announced its participation in the BioMilano 2003 Italian Partnering Conference in Milan, Italy today. BioMilano 2003 is a unique showcase to promote the development and growth of the biopharmaceutical industry by helping to initiate partnering opportunities between the pharmaceutical and financial communities in the United States and Italy. Luigi Lenaz, M.D., President Oncology Division, will present on behalf of Spectrum Pharmaceuticals.
Spectrum Pharmaceuticals' primary focus is to develop in-licensed drugs for the treatment and supportive care of cancer patients. The Company's lead drug, satraplatin, is a phase 3 oral, anti-cancer drug being co-developed with GPC Biotech AG, which has been granted fast-track status by the United States Food and Drug Administration. Elsamitrucin, a phase 2 drug, will initially target non-Hodgkin's lymphoma. Eoquin(TM) is being studied in the treatment of superficial bladder cancer, and may have applications as a radiation sensitizer. The Company is actively working to develop, seek approval for and oversee the marketing of generic drugs in the U.S. Spectrum also has a pipeline of pre-clinical neurological drug candidates for disorders such as attention-deficit hyperactivity disorder, schizophrenia, mild cognitive impairment and pain, which it is actively seeking to out-license or co-develop. For additional information about the Company, visit the Company's web site at . http://www.spectrumpharm.com/
This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements include but are not limited to statements that relate to the intent, belief, plans or expectations of the company or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include our lack of revenues and need for additional financing, the possibility that our existing drug product candidates may not prove to be safe or effective, our limited experience in establishing strategic alliances, our limited experience with the generic drug industry and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission.
For further information, please contact Rajesh C. Shrotriya, M.D., CEO and President of Spectrum Pharmaceuticals, Inc., +1-949-788-6700, ext. 295.
CONTACT: Rajesh C. Shrotriya, M.D., CEO and President of SpectrumPharmaceuticals, Inc., +1-949-788-6700, ext. 295
Web site: http://www.spectrumpharm.com/
Terms and conditions of use apply
Copyright © 2003 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: November 2003